BioCardia and Juventas Announce Phase II Development Program of JVS-100 ... MarketWatch (press release) The previous Phase I trial enrolled 17 NYHA Class III heart failure patients and showed promising safety and signals of clinical benefit to the patients treated. "JVS-100 provides the potential for an off the shelf regenerative medicine therapeutic, ... Regenerative medicine startup to begin enrollment in phase 2 heart failure trial |
